View in EDS HTML Full Text PDF Full Text

Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study.

Saved in:
Bibliographic Details
Title: Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study.
Authors: Huang XY; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Shi GM; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Zheng ZT; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Sun HC; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Liang F; Department of Statistics, Zhongshan Hospital, Fudan University, Shanghai, China., Ji Y; Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China., Chen Y; Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China., Yang GH; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Hu ZQ; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Lu JC; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Meng XL; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Guo XJ; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Zhang CC; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Fan J; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China., Zhou J; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China. zhou.jian@zs-hospital.sh.cn.
Source: BMC medicine [BMC Med] 2025 Oct 21; Vol. 23 (1), pp. 573. Date of Electronic Publication: 2025 Oct 21.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101190723 Publication Model: Electronic Cited Medium: Internet ISSN: 1741-7015 (Electronic) Linking ISSN: 17417015 NLM ISO Abbreviation: BMC Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41121202
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Huang+XY%22">Huang XY</searchLink>; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China.<br /><searchLink fieldCode="AU" term="%22Shi+GM%22">Shi GM</searchLink>; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China.<br /><searchLink fieldCode="AU" term="%22Zheng+ZT%22">Zheng ZT</searchLink>; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China.<br /><searchLink fieldCode="AU" term="%22Sun+HC%22">Sun HC</searchLink>; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China.<br /><searchLink fieldCode="AU" term="%22Liang+F%22">Liang F</searchLink>; Department of Statistics, Zhongshan Hospital, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Ji+Y%22">Ji Y</searchLink>; Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Chen+Y%22">Chen Y</searchLink>; Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Yang+GH%22">Yang GH</searchLink>; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China.<br /><searchLink fieldCode="AU" term="%22Hu+ZQ%22">Hu ZQ</searchLink>; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China.<br /><searchLink fieldCode="AU" term="%22Lu+JC%22">Lu JC</searchLink>; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China.<br /><searchLink fieldCode="AU" term="%22Meng+XL%22">Meng XL</searchLink>; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China.<br /><searchLink fieldCode="AU" term="%22Guo+XJ%22">Guo XJ</searchLink>; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China.<br /><searchLink fieldCode="AU" term="%22Zhang+CC%22">Zhang CC</searchLink>; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China.<br /><searchLink fieldCode="AU" term="%22Fan+J%22">Fan J</searchLink>; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China.<br /><searchLink fieldCode="AU" term="%22Zhou+J%22">Zhou J</searchLink>; Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, No.180 Fenglin Road, Shanghai, 200032, China. zhou.jian@zs-hospital.sh.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101190723%22">BMC medicine</searchLink> [BMC Med] 2025 Oct 21; Vol. 23 (1), pp. 573. <i>Date of Electronic Publication: </i>2025 Oct 21.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101190723 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1741-7015 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217417015%22">17417015 </searchLink><i>NLM ISO Abbreviation: </i>BMC Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41121202
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s12916-025-04404-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 573
    Titles:
      – TitleFull: Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Huang XY
      – PersonEntity:
          Name:
            NameFull: Shi GM
      – PersonEntity:
          Name:
            NameFull: Zheng ZT
      – PersonEntity:
          Name:
            NameFull: Sun HC
      – PersonEntity:
          Name:
            NameFull: Liang F
      – PersonEntity:
          Name:
            NameFull: Ji Y
      – PersonEntity:
          Name:
            NameFull: Chen Y
      – PersonEntity:
          Name:
            NameFull: Yang GH
      – PersonEntity:
          Name:
            NameFull: Hu ZQ
      – PersonEntity:
          Name:
            NameFull: Lu JC
      – PersonEntity:
          Name:
            NameFull: Meng XL
      – PersonEntity:
          Name:
            NameFull: Guo XJ
      – PersonEntity:
          Name:
            NameFull: Zhang CC
      – PersonEntity:
          Name:
            NameFull: Fan J
      – PersonEntity:
          Name:
            NameFull: Zhou J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 21
              M: 10
              Text: 2025 Oct 21
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1741-7015
          Numbering:
            – Type: volume
              Value: 23
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: BMC medicine
              Type: main
ResultId 1